Generic Bevyxxa Availability
Last updated on Apr 10, 2025.
Bevyxxa is a brand name of betrixaban, approved by the FDA in the following formulation(s):
BEVYXXA (betrixaban - capsule;oral)
-
Manufacturer: PORTOLA PHARMS INC
Approval date: June 23, 2017
Strength(s): 40MG (discontinued) [RLD], 80MG (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bevyxxa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Pharmaceutical salts and polymorphs of a factor Xa inhibitor
Patent 7,598,276
Issued: October 6, 2009
Inventor(s): Grant; Craig et al.
Assignee(s): Millenium Pharmaceuticals, Inc. (Cambridge, MA)The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I. ##STR00001##
Patent expiration dates:
- November 8, 2026✓
- November 8, 2026
-
Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
Patent 8,404,724
Issued: March 26, 2013
Inventor(s): Sinha Uma & Hollenbach Stanley J. & Abe Keith
Assignee(s): Millennium Pharmaceuticals, Inc.Unit doses of factor Xa inhibitor compounds and methods of using these compounds for inhibiting blood coagulation in a human patient are taught herein. The unit dose of the factor Xa inhibitor compounds disclosed herein required to inhibit coagulation in a primate is lower than the unit dose required to obtain similar levels of coagulation inhibition in other animal models, such as rodents. Also taught are in vitro assays useful in predicting in vivo antithrombotic activity in humans.
Patent expiration dates:
- March 29, 2031✓✓
- March 29, 2031
-
Methods of using crystalline forms of a salt of a factor Xa inhibitor
Patent 8,557,852
Issued: October 15, 2013
Inventor(s): Grant Craig & Kanter James P. & Langlands Graeme
Assignee(s): Millennium Pharmaceuticals, Inc.The present invention provides methods for preventing or treating a condition characterized by undesired thrombosis in a mammal using a crystalline polymorph form of a maleate salt of a compound of Formula I that has activity against mammalian factor Xa.
Patent expiration dates:
- September 8, 2028✓
- September 8, 2028✓
- September 8, 2028
-
Methods of synthesizing factor Xa inhibitors
Patent 8,987,463
Issued: March 24, 2015
Inventor(s): Pandey; Anjali et al.
Assignee(s): Millennium Pharmaceuticals, Inc. (Cambridge, MA); Portola Pharmaceuticals, Inc. (South San Francisco, CA)Described herein are novel methods of preparing a compound of Formula II or a pharmaceutically acceptable salt thereof. In some embodiments, the method is for preparing betrixaban or a pharmaceutically acceptable salt thereof. Also described are compositions comprising substantially pure betrixaban free base or salt thereof. ##STR00001##
Patent expiration dates:
- December 28, 2030✓
- December 28, 2030
-
Pharmaceutical salts and polymorphs of a factor Xa inhibitor
Patent 9,555,023
Issued: January 31, 2017
Inventor(s): Grant Craig & Kanter James P. & Langlands Graeme
Assignee(s): Millennium Pharmaceuticals, Inc.The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I.
Patent expiration dates:
- November 7, 2026✓
- November 7, 2026
More about Bevyxxa (betrixaban)
- Bevyxxa consumer information
- Check interactions
- Compare alternatives
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: factor Xa inhibitors
- Breastfeeding
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.